Thiopental

Published on 07/02/2015 by admin

Filed under Anesthesiology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 1 (1 votes)

This article have been viewed 1839 times

Thiopental

C. Thomas Wass, MD

Thiopental is no longer available in the United States because the governments of countries in which it is manufactured refuse to allow it to be exported to countries in which it is used for lethal injection. However, anesthesia providers should be familiar with the use of thiopental because, (1) from a historical perspective, for decades it was the most widely used intravenous drug to induce anesthesia and (2) thiopental is a core medicine on the World Health Organization’s Essential Drugs List. Thiopental is still widely used outside the United States, and anesthesia providers who travel to practice outside the United States for whatever reason must remain familiar with its pharmacokinetics and pharmacodynamics.

Barbituric acid (2,4,6,-trioxyhexahydropyrimidine) (Figure 71-1) was first synthesized by Adolph von Bäyer (founder of what was to become the Bayer chemical company) in 1864. Although this molecule is the structural framework from which barbiturates are derived, it is devoid of anesthetic properties. Structural modification at the number 2 and 5 carbon atoms results in barbiturate drugs that have sedative-hypnotic properties. For example, addition of a benzene ring at the C5 position results in phenobarbital, a drug first used for its sedative properties in the early 1900s and still one of the most widely used drugs in the world to treat seizure disorders. With the lack of thiopental in the United States, intensive care physicians are using phenobarbital to induce barbiturate coma in patients with raised intracranial pressure unresponsive to other therapies. Replacement of the oxygen atom with a sulfur atom at the C2 position and adding a large aliphatic carbon group to the C5 atom transforms barbituric acid into thiopental. Clinically, sodium thiopental was first administered in 1934 by Ralph Waters at the University of Wisconsin, Madison, and by John Lundy at the Mayo Clinic in Rochester, MN.

Commercially available thiopental [5-ethyl-5-(1-methyl-butyl)-2-thiobarbituric acid] is a racemic mixture of stereoisomers [the S(−) isomer is twice as potent as the R(+) counterpart] that is water soluble and highly alkaline (pKa of 7.6 and pH of 10.5). Decreased pH (e.g., mixing with opioids, catecholamines, or neuromuscular blocking agents) may result in precipitation. Reconstitution with Ringer’s lactate solution is not recommended. Refrigerated thiopental is stable for approximately 1 week following reconstitution with sterile water. Both isomers exert their biologic activity by enhancing and mimicking the action of γ-aminobutyric acid (GABA) at GABAA receptors.

Pharmacokinetics

Distribution of intravenously administered drugs throughout body tissues is determined by tissue blood flow, blood-tissue concentration gradient, lipid solubility, extent of protein binding, and degree of ionization. Thiopental is very lipid soluble and, thus, readily crosses the blood-brain barrier. Other pharmacokinetic properties of thiopental are listed in Table 71-1. Decreased protein binding (e.g., in patients with uremia or cirrhosis) increases the free fraction of drug available to interact with GABA receptors in the brain.

Table 71-1

Induction Dose, Half-Life, and Metabolism/Route of Elimination for Commonly Used Intravenous Anesthetic Agents

Drug Induction Dose Elimination Half-Life (h) Metabolism/Elimination
Etomidate 0.1-0.3 mg/kg 2.9-5.3 HepaticRenal
Fentanyl 10-20 μg/mg 0.25 HepaticRenal
Ketamine 1-2 mg/kg 2.5-2.8 HepaticRenal
Midazolam 1-2 mg/kg 1.7-2.6 HepaticRenal
Morphine 1 mg/kg 2-4 HepaticRenal
Propofol 1-3 mg/kg 4-7 HepaticRenal
Thiopental 3-5 mg/kg 7-17 HepaticRenal

image

Because the brain is a highly perfused (i.e., belongs to the vessel-rich organ group) relatively low-volume organ, cerebral thiopental concentrations equilibrate rapidly with the central blood pool (Figure 71-2), resulting in depressed electroencephalographic activity—and induction of anesthesia—within 20 to 40 sec.

image
Figure 71-2 Distribution, redistribution, and metabolism of thiopental following intravenous bolus. VRG, Vessel-rich group. (Modified from Stoelting RK, Hillier SC. Barbiturates. In: Stoelting RK, ed. Handbook of Pharmacology and Physiology in Anesthetic Practice. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005:119-131.)

After achieving maximal concentration within the central nervous system, thiopental follows its concentration gradient into the central blood pool and is subsequently redistributed to a relatively large skeletal muscle reservoir. As a result, electroencephalographic activity returns toward baseline—and patients emerge from anesthesia—within 5 to 8 min. That is, redistribution is the primary mechanism responsible for prompt awakening following an induction dose of thiopental. But when thiopental is administered in multiple doses or as a continuous infusion, skeletal muscle becomes progressively saturated and eventually equilibrates with the central blood pool, thereby preventing further uptake by this large tissue reservoir. At that point, further decreases in blood thiopental concentrations occur more slowly and become dependent on uptake by less well perfused organs (e.g., adipose) as well as hepatic metabolism.

Thiobarbiturate metabolism occurs primarily in hepatic endoplasmic reticulum; however, a small fraction of drug may undergo extrahepatic (e.g., kidney) biotransformation. Biologic reactions responsible for the production of inactive water-soluble metabolites include oxidation of substituents on the C5 atom, desulfurization on the C2 atom, and hydrolytic opening of the barbituric acid ring. Of additional interest, hepatic clearance is characterized as a low hepatic extraction ratio, and thus, thiopental metabolism is more dependent on hepatic enzyme (e.g., P-450 oxidase) activity than on hepatic blood flow.

Finally, thiopental is eliminated from the body by renal excretion (99% as inactive metabolites, 1% unchanged as active metabolite). The degree of protein binding substantially affects renal glomerular filtration and tubular reabsorption. For example, competitive displacement of thiopental from plasma proteins (primarily albumin) by aspirin, phenylbutazone, or uremic toxins results in enhanced drug effect because of increased free-drug fraction and greater renal tubular reabsorption.

Side effects and adverse effects

Transient hypotension following an intravenously administered bolus of thiopental is primarily due to peripheral vasodilation resulting from decreased sympathetic tone. Cardiac output is minimally affected. Decreased activity in the medullary and pontine ventilatory centers produce dose-dependent respiratory depression. Barbiturates can stimulate δ-aminolevulinic acid synthetase, which can precipitate a crisis in patients with acute intermittent porphyria.

Inadvertent intra-arterial injection of thiopental causes intense vasoconstriction and pain along the arterial distribution. Tissue damage occurs as a result of (1) reactive vasoconstriction, (2) occlusive thiopental crystal formation, and (3) inflammatory mediated arteritis. Treatment consists of immediate dilution (with 0.9% saline solution) and vasomotor relaxation (e.g., lidocaine, papaverine, or phenoxybenzamine) injected into the offending catheter. Sympathectomy (e.g., brachial plexus or stellate ganglion block) may also alleviate vasoconstriction.